Lineage Cell Therapeutics (LCTX) said Tuesday it started a clinical study evaluating OPC1, an investigational allogeneic stem cell-derived transplant for spinal cord injury.
OPC1 is designed to replace or support spinal cord cells that are absent or dysfunctional due to traumatic injury, aiming to restore or enhance functional activity in affected individuals, the company said.
The company said the study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System, a novel device developed to deliver OPC1 directly to the injury site.
It will enroll both subacute patients, treated between 21 and 42 days after injury, and chronic spinal cord injury patients, treated between one and five years after injury, according to the company.
Shares of Lineage Cell Therapeutics were down more than 2% in recent trading.
Price: 0.64, Change: -0.02, Percent Change: -2.29
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。